{
    "id": 5828,
    "name": "endometrioid ovary carcinoma",
    "source": "DOID",
    "definition": "An ovary adenocarcinoma that has_material_basis_in endometrial tissue. [url:https\\://www.ncbi.nlm.nih.gov/pubmed/25120828]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5828",
    "evidence": [
        {
            "id": 1651,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, AZD5363 demonstrated safety and efficacy in patients with advanced solid tumors, including prolonged stable disease in one patient with a PIK3CA-mutant endometrioid ovarian cancer (American Association for Cancer Research; 06 Apr 2013-10 Apr 2013; Abstract LB-66).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5828,
                "name": "endometrioid ovary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1761,
                    "pubMedId": null,
                    "title": "Results of two Phase 1 multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.",
                    "url": "https://www.escholar.manchester.ac.uk/uk-ac-man-scw:194446"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10735,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment increased Tp53 and Cdkn1a protein levels, resulted in growth inhibition of TP53 wild-type endometrioid ovary carcinoma cells in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2999,
                "therapyName": "thioureidobutyronitrile",
                "synonyms": null
            },
            "indication": {
                "id": 5828,
                "name": "endometrioid ovary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8790,
                    "pubMedId": null,
                    "title": "Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies",
                    "url": "http://www.abstractsonline.com/pp8/#!/4292/presentation/3876"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02282020",
            "title": "Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02345265",
            "title": "Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02446600",
            "title": "Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 8341,
                    "therapyName": "Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02584478",
            "title": "Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7370,
                    "therapyName": "Anlotinib + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02759588",
            "title": "GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6364,
                    "therapyName": "GL-ONC1",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02889900",
            "title": "Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03348631",
            "title": "Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2683,
                    "therapyName": "Tazemetostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03395080",
            "title": "A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204) (P204)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6244,
                    "therapyName": "DKN-01",
                    "synonyms": null
                },
                {
                    "id": 6254,
                    "therapyName": "DKN-01 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03402841",
            "title": "Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03587311",
            "title": "Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7173,
                    "therapyName": "Anetumab ravtansine + Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 2123,
                    "therapyName": "Bevacizumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03695380",
            "title": "A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7550,
                    "therapyName": "Atezolizumab + Cobimetinib + Niraparib",
                    "synonyms": null
                },
                {
                    "id": 7549,
                    "therapyName": "Cobimetinib + Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03737643",
            "title": "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7489,
                    "therapyName": "Bevacizumab + Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7490,
                    "therapyName": "Bevacizumab + Durvalumab + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 2117,
                    "therapyName": "Bevacizumab + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03840200",
            "title": "A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7867,
                    "therapyName": "Ipatasertib + Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03955471",
            "title": "A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients With Platinum Resistant Ovarian Cancer (MOONSTONE)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6321,
                    "therapyName": "Niraparib + TSR-042",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04034927",
            "title": "Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 8289,
                    "therapyName": "Olaparib + Tremelimumab",
                    "synonyms": null
                }
            ]
        }
    ]
}